dr. gandhi discusses the role of alectinib in alk lung cancer
Published 6 years ago • 310 plays • Length 0:41Download video MP4
Download video MP3
Similar videos
-
1:48
dr. gandhi on sequencing and emerging agents in alk nsclc
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer
-
1:12
dr. christina baik on alectinib in patients with alk-lung cancer
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
5:52
ceritinib and alectinib in relapsed alk nsclc
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
3:59
alectinib in alk-mutated nsclc
-
1:55
dr. villaflor discusses alectinib in alk nsclc
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc
-
2:45
dr. govindan on the potential for alectinib
-
2:26
dr. shaw on alectinib as first-line therapy in lung cancer
-
7:13
alectinib for relapsed/refractory alk nsclc
-
1:17
dr. christina baik on alectinib versus crizotinib in alk-positive lung cancer
-
6:41
next-generation alk inhibitors for nsclc
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
3:53
how to maximize clinical benefits for patients with alk-positive non-small cell lung cancer
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc